Endurant Capital Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Endurant Capital Management’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-4,700	Closed	-$281K	–	106
2017 Q2	$281K	Buy	4,700 +700	+18%	+$39.1K	0.08%	89
2017 Q1	$213K	Sell	4,000 -10,800	-73%	-$641K	0.07%	87
2016 Q4	$739K	Buy	14,800 +9,000	+155%	+$482K	0.31%	59
2016 Q3	$348K	Buy	+5,800	New	+$334K	0.13%	82
2016 Q2	–	Sell	-17,500	Closed	-$516K	–	98
2016 Q1	$516K	Buy	+17,500	New	+$552K	0.17%	70

Other funds holding ONCE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Endurant Capital Management's ONCE Position: Q3 2017 in Review

Endurant Capital Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q3 2017, closing a stake of 4,700 shares — an estimated $281K sold.

Endurant Capital Management first reported a position in ONCE in Q1 2016 and held it in 5 quarters. The position peaked at $739K in Q4 2016. 163 funds tracked by Wall St. Rank hold ONCE as of Q3 2017.

Endurant Capital Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
Endurant Capital Management sold 4,700 Spark Therapeutics, Inc. Common Stock shares in Q3 2017, an estimated $281K.
Endurant Capital Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2016 and held it in 5 quarters.
Endurant Capital Management's Spark Therapeutics, Inc. Common Stock position peaked at $739K in Q4 2016.
163 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q3 2017.

Based on Endurant Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.